People · Operator
Named in public records as an officer, director or promoter · active 2013–2013 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intra Cellular Therapies Inc | — | Pharmaceuticals | Series C | $80.9M | $2.1B | 2013 |
| Intra-Cellular Therapies, Inc. | — | Biotechnology | Series C | $70.3M | $2.9B | 2013 |
Kimberly Vanover at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kimberly Vanover on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sharon Mates | 2 | 2 |
| Lawrence Wennogle | 2 | 2 |
| Allen Fienberg | 2 | 2 |
| Lawrence Hineline | 2 | 2 |
| Joel Marcus | 1 | 9 |
| Richard Lerner | 1 | 5 |
| Michael Rawlins | 1 | 1 |
| Christopher Alafi | 1 | 1 |
| Sir Michael J. Rawlins | 1 | 1 |
| David J. Kipnis | 1 | 1 |
| Joel J. Marcus | 1 | 1 |
| Richard J. Lerner | 1 | 1 |
| Christopher J. Alafi | 1 | 1 |
| Lawrence J. Hineline | 1 | 1 |
| Samir Nasri | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.